logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer Updates US Labels For Drospirenone-containing Combined Oral Contraceptives

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said the company and U.S. Food and Drug Administration, or FDA, have agreed to update the labels for its drospirenone-containing combined oral contraceptives, or COCs, in United States.

The updated labels in the U.S. include additional information from recently published studies evaluating the risk of venous thromboembolism (blood clots) in women taking drospirenone-containing COCs. Mainly, the new U.S. labels state that COCs containing drospirenone may be associated with a higher risk of venous thromboembolism, or VTE, than COCs containing levonorgestrel or some other progestins, Bayer HealthCare noted.

Epidemiologic studies that compared the risk of VTE reported that the risk ranged from no increase to a three-fold increase. The U.S. labels state that before initiating use of drospirenone-containing COCs in a new COC user or a woman who is switching from a contraceptive that does not contain drospirenone, consider the risks and benefits of a drospirenone containing COC in light of her risk of a VTE.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
UK-based oil giant BP Plc. and French peer Total SA Tuesday reported lower profit for the first quarter, as oil prices declined sharply from the previous year. However, results reflected stronger overall refining environment. Hartford Financial reported a decline in first-quarter profit, despite growth in premiums, due mainly to the absence of gains recorded last year. Apple Inc. said Monday after the markets closed that its second quarter profit rose 33% from last year, driven by strong sales of iPhone and Mac as well as all-time record performance of the App Store. The company's quarterly earnings per share also breezed past Wall Street expectations as did its quarterly sales.
comments powered by Disqus
Follow RTT